<div id="readability-page-1"><p><span>Teladoc Health (NYSE:TDOC - Get Free Report)</span> was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage presently has a $11.00 target price on the health services provider's stock. Deutsche Bank Aktiengesellschaft's price target points to a potential upside of 107.35% from the stock's previous close.</p><div><p><span></span><span>Get <strong>Teladoc Health</strong> alerts:</span></p></div><ul><li>2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick</li></ul><p>Several other equities analysts also recently commented on the stock. Oppenheimer lowered their target price on shares of Teladoc Health from $12.00 to $7.00 and set an &#34;outperform&#34; rating on the stock in a report on Tuesday, March 3rd. Canaccord Genuity Group lowered their target price on shares of Teladoc Health from $12.00 to $10.00 and set a &#34;buy&#34; rating on the stock in a report on Thursday, February 26th. Wells Fargo &amp; Company decreased their price target on Teladoc Health from $8.00 to $6.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Thursday, February 26th. Barclays assumed coverage on shares of Teladoc Health in a research report on Tuesday, December 9th. They set an &#34;equal weight&#34; rating and a $8.50 price target for the company. Finally, Citigroup dropped their price objective on shares of Teladoc Health from $9.00 to $6.00 and set a &#34;neutral&#34; rating for the company in a research note on Tuesday, March 3rd. Six research analysts have rated the stock with a Buy rating, thirteen have assigned  a Hold rating and one  has assigned  a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $7.76.</p><p><b>Check Out Our Latest Report on Teladoc Health</b></p><h2>Teladoc Health Price Performance</h2><ul><li>2 Former Pandemic Darlings Eyeing a Big 2025 Turnaround</li></ul><p>NYSE TDOC opened at $5.31 on Tuesday. The company has a 50 day moving average price of $5.75 and a two-hundred day moving average price of $7.11. The company has a quick ratio of 2.67, a current ratio of 2.77 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $946.41 million, a PE ratio of -4.65 and a beta of 2.13. Teladoc Health has a 12-month low of $4.40 and a 12-month high of $9.77. </p><p>Teladoc Health (NYSE:TDOC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.13%. The company had revenue of $642.27 million during the quarter, compared to the consensus estimate of $635.33 million. During the same period in the prior year, the business posted ($0.28) EPS. The company's quarterly revenue was up .3% on a year-over-year basis. Teladoc Health has set its Q1 2026 guidance at -0.450--0.350 EPS and its FY 2026 guidance at -1.100--0.700 EPS.  As a group, equities analysts predict that  Teladoc Health will post -1.16 earnings per share for the current fiscal year. </p><h2>Insider Activity at Teladoc Health</h2><ul><li>Can the New CEO Revive This Struggling Telehealth Stock?</li></ul><p>In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total value of $130,762.94. Following the sale, the chief executive officer directly owned 201,036 shares in the company, valued at $1,533,904.68. This represents a 7.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own  0.58% of the company's stock. </p><h2>Institutional Trading of Teladoc Health</h2><p>A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of  Teladoc Health by 4.2% during the third quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider's stock worth $169,372,000 after acquiring an additional 891,732 shares during the last quarter.  Dimensional Fund Advisors LP raised its holdings in  Teladoc Health by 8.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 7,494,255 shares of the health services provider's stock worth $52,459,000 after purchasing an additional 605,061 shares in the last quarter.  Geode Capital Management LLC lifted its position in shares of  Teladoc Health by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider's stock valued at $29,324,000 after buying an additional 18,394 shares in the last quarter.  Jupiter Asset Management Ltd. increased its holdings in shares of  Teladoc Health by 293.9% in the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider's stock valued at $27,021,000 after acquiring an additional 2,880,008 shares during the period.  Finally, Nuveen LLC boosted its holdings in  Teladoc Health by 38.7% during the fourth quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider's stock worth $18,618,000 after buying an additional 742,240 shares in the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds. </p><h2>Teladoc Health Company Profile</h2> (Get Free Report)<p>Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.  </p><p>Teladoc's service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Teladoc Health</li><li>Buy this Gold Stock Before May 15th, 2026</li><li>Read this or regret it forever</li><li>J.P. Morgan is betting on this coin</li><li>Central banks just did something they haven’t done since 1967</li><li>My Epstein Story</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRET0M?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRET0M"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Teladoc Health Right Now?</h2><p>Before you consider Teladoc Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.</p><p>While Teladoc Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

HEAL

TDOC

EDOC

FDHT

<p>Deutsche Bank Aktiengesellschaft upgraded Teladoc Health (NYSE:TDOC) from a "hold" to a "buy" rating, setting a price target of $11.00, indicating a potential upside of 107.35%. Other analysts have varied opinions, with Oppenheimer lowering their target to $7.00 and Canaccord Genuity to $10.00. Currently, Teladoc has a consensus rating of "Hold" with a target of $7.76. The stock opened at $5.31, with a market cap of $946.41 million and a recent quarterly EPS of ($0.14), exceeding estimates. CEO Charles Divita III sold shares, reducing his stake by 7.86%.</p>

Teladoc Health (NYSE:TDOC) Upgraded at Deutsche Bank Aktiengesellschaft